Aethlon Stock Surges 103% After First Patient Treated In HEMOPURIFIER Trial

Medical device technology company Aethlon Medical (NASDAQ: AEMD) shares are surging premarket on Wednesday after the company said the first patient has been treated in its first-in-human visibility Early Feasibility Study (EFS) evaluating HEMOPURIFIER.

The study is treating patients with recurrent cancer and/or metastatic squamous cell carcinoma, a type of cancer of the head and neck. Aethlon is evaluating “the HEMOPURIFIER for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA).”

The EFS is the device equivalent of a Phase 1 trial for drugs and is a single centre open-label trial in 10-12 subjects.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

“The initiation of this first-in-human study addressing cancer-associated exosomes is a significant step towards evaluating the HEMOPURIFIER® for potentially improving the efficacy of KEYTRUDA® in head and neck cancer,” commented Charles J Fisher Jr, Aethlon’s CEO.

Aethlon shares are up 103% at the time of this publication, trading at $3.29 after closing Tuesday’s session at $1.62.